Angle PLC
LSE:AGL
Intrinsic Value
ANGLE Plc operates as a holding company, through its subsidiaries engages in providing products in cancer diagnostics and foetal health. [ Read More ]
The intrinsic value of one AGL stock under the Base Case scenario is 13.81 GBX. Compared to the current market price of 12.25 GBX, Angle PLC is Undervalued by 11%.
Valuation Backtest
Angle PLC
Run backtest to discover the historical profit from buying and selling AGL stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Angle PLC
Current Assets | 29.5m |
Cash & Short-Term Investments | 22.2m |
Receivables | 5.1m |
Other Current Assets | 2.3m |
Non-Current Assets | 10.6m |
PP&E | 7.9m |
Intangibles | 2.7m |
Current Liabilities | 3.9m |
Accounts Payable | 2.9m |
Other Current Liabilities | 1.1m |
Non-Current Liabilities | 4.2m |
Long-Term Debt | 4m |
Other Non-Current Liabilities | 201k |
Earnings Waterfall
Angle PLC
Revenue
|
1.8m
GBP
|
Cost of Revenue
|
-723k
GBP
|
Gross Profit
|
1.1m
GBP
|
Operating Expenses
|
-25.6m
GBP
|
Operating Income
|
-24.5m
GBP
|
Other Expenses
|
2.2m
GBP
|
Net Income
|
-22.3m
GBP
|
Free Cash Flow Analysis
Angle PLC
What is Free Cash Flow?
AGL Profitability Score
Profitability Due Diligence
Angle PLC's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Score
Angle PLC's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
AGL Solvency Score
Solvency Due Diligence
Angle PLC's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Score
Angle PLC's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AGL Price Targets Summary
Angle PLC
According to Wall Street analysts, the average 1-year price target for AGL is 71.4 GBX with a low forecast of 70.7 GBX and a high forecast of 73.5 GBX.
Shareholder Return
AGL Price
Angle PLC
Average Annual Return | 13.97% |
Standard Deviation of Annual Returns | 92.3% |
Max Drawdown | -94% |
Market Capitalization | 31.9m GBX |
Shares Outstanding | 260 467 288 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
ANGLE Plc operates as a holding company, through its subsidiaries engages in providing products in cancer diagnostics and foetal health. The company is headquartered in Guildford, Surrey and currently employs 102 full-time employees. The company went IPO on 2004-03-17. The Company’s lead product is the Parsortix cell separation system, which captures very rare cells from the blood. This includes circulating tumor cells (CTCs) in cancer patient blood even when there is less than one CTC in one billion healthy cells. The Parsortix cell separation system uses a microfluidic technology in the form of a one-time use cassette to capture and then harvest circulating tumor cells (CTCs) from blood. The cassette captures CTCs based on their less deformable nature and larger size compared to other blood components. The Company’s translational research includes ovarian cancer, breast cancer, prostate cancer and small cell lung cancer.
Contact
IPO
Employees
Officers
The intrinsic value of one AGL stock under the Base Case scenario is 13.81 GBX.
Compared to the current market price of 12.25 GBX, Angle PLC is Undervalued by 11%.